Compare BFLY & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFLY | EBS |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.0M | 529.9M |
| IPO Year | N/A | 2006 |
| Metric | BFLY | EBS |
|---|---|---|
| Price | $3.06 | $11.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 6.4M | 871.0K |
| Earning Date | 10-31-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.35 |
| Revenue | $88,447,000.00 | ★ $788,900,000.00 |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $16.00 | $15.21 |
| P/E Ratio | ★ N/A | $8.81 |
| Revenue Growth | ★ 16.04 | N/A |
| 52 Week Low | $1.32 | $4.02 |
| 52 Week High | $4.98 | $13.41 |
| Indicator | BFLY | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 62.23 |
| Support Level | $2.69 | $10.63 |
| Resistance Level | $3.41 | $12.28 |
| Average True Range (ATR) | 0.25 | 0.59 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 77.15 | 86.96 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. The company enables the practical application of ultrasound information in the clinical workflow. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. With its small, handheld size, low cost, and simple user interface.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.